{"nctId":"NCT00257166","briefTitle":"Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)","startDateStruct":{"date":"2006-01"},"conditions":["Bipolar Disorder"],"count":238,"armGroups":[{"label":"Ziprasidone oral capsules","type":"EXPERIMENTAL","interventionNames":["Drug: Ziprasidone oral capsules"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo oral capsules"]}],"interventions":[{"name":"Ziprasidone oral capsules","otherNames":[]},{"name":"placebo oral capsules","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* DSM-IV criteria for Bipolar I disorder (manic or mixed); age 10 - 17 years\n\nExclusion Criteria:\n\n* Imminent risk of suicide or homicide, as judged by the site investigator; any history of serious or unstable medical illness, including risk for QT prolongation","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Young Mania Rating Scale (YMRS) Score at Week 4","description":"YMRS: an 11-item scale that measured the severity of manic episodes. Four items were rated on a scale from 0 (symptom absent) to 8 (symptom extremely severe). The remaining items were rated on a scale from 0 (symptom absent) to 4 (symptom extremely severe). YMRS total score ranged from 0 to 60, higher score indicated higher severity of mania.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":"6.6"},{"groupId":"OG001","value":"27.0","spread":"6.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.8","spread":"7.8"},{"groupId":"OG001","value":"-9.9","spread":"7.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Young Mania Rating Scale (YMRS) Score at Week 1, 2 and 3","description":"YMRS: an 11-item scale that measured the severity of manic episodes. Four items were rated on a scale from 0 (symptom absent) to 8 (symptom extremely severe). The remaining items were rated on a scale from 0 (symptom absent) to 4 (symptom extremely severe). YMRS total score ranged from 0 to 60, higher score indicated higher severity of mania.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.3","spread":"7.5"},{"groupId":"OG001","value":"-6.3","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.5","spread":"8.7"},{"groupId":"OG001","value":"-8.1","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","spread":"8.1"},{"groupId":"OG001","value":"-9.0","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 1, 2, 3 and 4","description":"CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"0.7"},{"groupId":"OG001","value":"4.5","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.8"},{"groupId":"OG001","value":"-0.5","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.0"},{"groupId":"OG001","value":"-0.6","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.0"},{"groupId":"OG001","value":"-0.7","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.1"},{"groupId":"OG001","value":"-0.9","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression - Improvement (CGI-I) Score","description":"CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.9"},{"groupId":"OG001","value":"3.4","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.1"},{"groupId":"OG001","value":"3.2","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.0"},{"groupId":"OG001","value":"3.1","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"1.0"},{"groupId":"OG001","value":"2.8","spread":"1.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":149},"commonTop":["Sedation","Headache","Somnolence","Fatigue","Nausea"]}}}